A Phase 1/2 interventional study of SAR443579 and venetoclax in Acute Myeloid Leukemia, sponsored by Sanofi. Terminated at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Sanofi · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Leukemia, Myeloid, Acute by Sanofi — none open to participants now, none under way, none of them phase 3. Leukemia, Myeloid, Acute · Sanofi.
Among the 16 studies in Leukemia, Myeloid, Acute by Sanofi, this one is the 12th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2024, is one of 3 in phase 1/2, and was the 16th registered.
3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →None of the 16 studies in Leukemia, Myeloid, Acute by Sanofi is open now. The open studies under Leukemia, Myeloid, Acute, anywhere →
Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 9 · Phase 3 1
First in 1997; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7 is below the median of 40 across 3,010 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 40 across the 15 interventional studies. Of the 14 that completed or were terminated, 6 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,560 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Leukemia, Myeloid, Acute by Sanofi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was a parallel, Phase 1/Phase 2, randomized, open label, multi-cohort, multi-center study assessing the safety, tolerability and preliminary efficacy of SAR443579 with different agents for treatment in adolescent and/or adult participants with CD123 expressing hematological malignancies.
This protocol was structured as a master protocol (containing common protocol elements). Individual sub-studies would explore SAR443579 with combination partners, which might include approved or investigational agents.
Experimental sub-studies would be tested through 3 parts:
Part 1: dose finding (such as dose escalation/ safety run-in). Part 2: dose optimization (when applicable). Part 3: dose expansion. In each sub-study, a dose escalation would identify preliminary recommended dose for expansion (pRDE) of SAR443579 and its respective combination partner. Following the determination of the preliminary RDE, additional participants would be enrolled in the dose expansion part, or if dose optimization needs to be further evaluated, additional participants would be enrolled in the "dose optimization/expansion" part. Dose optimization and dose expansion part could involve randomization depending on specific sub-study design.
Study consisted of a screening period, treatment period, and follow-up period. Participants would receive study treatment until documented disease progression, unacceptable adverse events, participant's decision to stop study treatment, or completion of the maximum cycles allowed in the sub-studies, or the participant met other criteria for discontinuation per study protocol (whichever occurred first).
Substudy 01:
Title: A Phase 1/Phase 2, open-label, multi-center study, assessing the safety, tolerability and the preliminary efficacy of SAR443579 administered in combination with azacitidine + venetoclax in adult participants with CD123 expressing newly diagnosed Acute Myeloid Leukemia (ND-AML) that are ineligible for intensive chemotherapy
Short title: A study to investigate natural killer cell engager (SAR443579) in combination with azacitidine + venetoclax in adult participants with newly diagnosed acute myeloid leukemia
The expected duration of the study for a participant was approximately about 2.5 years. The study duration includes a screening period, an induction and maintenance. After the end of study treatment participants would enter the follow-up period for up to 2 years.
Planned number of participants:
22 participants planned to be screened, 8 being adults and 14 being elderly; 9-18 participants planned to be enrolled (dose escalation part)
Enrollment would be paused upon completion of Part 1: Dose Escalation. The available data would be reviewed and the recommended doses and schedule for optimization would be selected by the study board. Enrollment in the Part 2: Dose optimization and Part 3: Dose expansion would be provided in a future protocol amendment.
The criteria were revised on the registry on Oct 19, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Participants with CD123-expressing hematological neoplasm per the 5th edition of the WHO Classification of Hematolymphoid Tumors.
Substudy 01:
A) ≥ 75 years of age, OR
B) 18 to 74 years of age and meeting one or more of the following:
Moderate hepatic impairment with total >1.5 to ≤3.0x (ULN).
a) 0 to 2 for participants ≥75 years of age or b) 0 to 3 for participants 18 to 74 years of age.
Participant with adequate liver function demonstrated by the following:
Exclusion Criteria:
Known acquired immunodeficiency syndrome (AIDS-related illnesses) or disease requiring antiretroviral treatment, or having active or C infection, or SARS-CoV-2 infection. With exception for:
Substudy 01:
Participant had received treatment with at least one of the following:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part 1: Safety run-in: SAR443579 treatment will begin with an identified starting dose. Safety run-in will proceed according to the incidence of DLTs.
Biological: SAR443579 · Drug: venetoclax · Drug: azacitidine
Pharmaceutical form: Powder for solution for infusion Route of administration: intravenous infusion
Pharmaceutical form :Film coated tablet Route of administration: oral
Also known as: VENCLYXTO / VENCLEXTA
Pharmaceutical form: Lyophilized powder for suspension for injection Route of administration: intravenous or subcutaneous
Sub-study 1: Part 1: Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLTs)
DLT=any of the following events during Cycle 1 (first 28 days) using NCI CTCAE v5.0 or ASTCT criteria, whether related or not to study treatment in absence of clear evidence to the contrary, and if not related to disease progression. Hematologic DLTs :toxicities, bone marrow hypocellularity, decreased neutrophils, febrile neutropenia, decreased platelets, anemia (all Grade 4) and Grade 3 thrombocytopenia. Non-hematologic DLTs: organ toxicities or infusion reaction (both Grade 4), Grade 3 infusion reaction lasting \>24 hours, Hy's law cases, Grade 3-4 infection, Grade 3 electrolyte abnormalities or transaminitis elevation, Grade \>=3 toxicities except alopecia, Grade 3 fatigue, asthenia, fever, anorexia, constipation, nausea, vomiting, diarrhea, infection, bleeding, Grade 3 cytokine release syndrome or laboratory abnormalities, Grade 3 or 4 tumor lysis syndrome. Any treatment related toxicity causing \>2-week delay in recovery to baseline/Grade \<=1 or requiring dose reduction/withdrawal.
Time frame: From Day 1 to Day 28 of Cycle 1 (each cycle was 28 days)
Sub-study 1: Part 2: Dose Optimization: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (SAEs) and Treatment-emergent Adverse Events of Special Interest (AESIs)
An AE was any untoward medical occurrence in participant or clinical study participant temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE was any AE, that at any dose: resulted in death, was life-threatening, required inpatient hospitalization/prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was a medically important event. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required. The TEAEs were defined as AEs that developed, worsened or became serious after the first administration of study treatment up to 30 days after the last administration of study treatment.
Time frame: AEs were planned to be collected from first dose of study treatment (Day 1) up to 30 days post last dose of study treatment
Sub-study 1: Part 2: Dose Optimization: Number of Participants With Potentially Clinically Significant Abnormalities (PCSA) in Hematology Parameters
Blood samples were planned to be collected to determine the PCSA in hematology.
Time frame: Planned to be collected from first dose of study treatment (Day 1) up to 30 days post last dose of study treatment
Sub-study 1: Part 2: Dose Optimization: Number of Participants With Potentially Clinically Significant Abnormalities in Clinical Chemistry Parameters
Blood samples were planned to be collected to determine the PCSA in clinical chemistry.
Time frame: Planned to be collected from first dose of study treatment (Day 1) up to 30 days post last dose of study treatment
Sub-study 1: Part 2: Dose Optimization: Complete Remission (CR) Rate
The CR rate was defined as percentage of participants who had a CR determined by the Investigator according to 2022European Leukemia Net (ELN) recommendations for diagnosis and management of AML.
Time frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenancecycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause,whichever occurred first
Sub-study 1: Part 3: Dose Expansion: Complete Remission (CR) Rate
The CR rate was defined as percentage of participants who had a CR determined by the Investigator according to 2022 European Leukemia Net (ELN) recommendations for diagnosis and management of AML.
Time frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
Sub-study 1: Part 1: Dose Escalation and Part 3: Dose Expansion: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), TE Serious Adverse Events (TESAEs) and TE Adverse Events of Special Interest (TEAESIs)
An AE was any untoward medical occurrence in participant or clinical study participant temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE was any AE, that at any dose: resulted in death, was life-threatening, required inpatient hospitalization/prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was a medically important event. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required. TEAEs: AEs that developed, worsened/became serious after first administration of study treatment up to 30 days after last administration of study treatment.
Time frame: From the first dose of study drug administration (Day 1) up to early termination of the study, maximum treatment duration was 31.3 weeks
Sub-study 1: Part 3: Dose Expansion: Percentage of Participants With Minimal Residual Disease
The minimal residual disease rate was defined as the percentage of participants with minimal residual disease as defined by 2022 ELN in participants achieving a CR, CR with partial hematologic recovery (CRh) or CR with incomplete hematologic recovery (CRi).
Time frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
Sub-study 1: All 3 Parts: Concentrations Observed at the End of Dosing Period During Repeated Administration (Ctrough) of SAR443579
Blood samples were collected just before treatment administration during repeated dosing to determine the Ctrough of SAR443579 during dose escalation part. Participants missed few scheduled site visits for sample collection and only participants with data collected at specified timepoints are reported.
Time frame: Part 1:Dose escalation (dose levels 1 and 2): Pre-dose: At Days 1, 8, 15 and 22 of Cycle 1 and Days 8, 15, 22 and 28 of Cycle 2 (each cycle was 28 days)
Sub-study 1: All 3 Parts: Maximum Plasma Concentration Observed (Cmax) of Venetoclax
Blood samples were collected at specified timepoints to determine Cmax of venetoclax during dose escalation part. Participants missed few scheduled site visits for sample collection and only participants with data collected at specified timepoints are reported.
Time frame: Part 1:Dose escalation (dose levels 1 and 2):Pre-dose and 2, 3, 4, 6, 11 and 24 hours post-dose on Cycle 1 Day 1; pre-dose and 2, 3, 4, 6, 9, 11 and 24 hours post-dose on Cycle 1 Day 8
Sub-study 1: All 3 Parts: Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC) of Venetoclax
Blood samples were collected at specified timepoints to determine AUC of venetoclax during dose escalation part. Participants missed few scheduled site visits for sample collection and only participants with data collected at specified timepoints are reported.
Time frame: Part 1:Dose escalation (dose levels 1 and 2):Pre-dose and 2, 3, 4, 6, 11 and 24 hours post-dose on Cycle 1 Day 1
Sub-study 1: All 3 Parts: Maximum Plasma Concentration Observed of Azacitidine
Blood samples were collected at specified timepoints to determine Cmax of azacitidine during dose escalation part. Participants missed few scheduled site visits for sample collection and only participants with data collected at specified timepoints are reported. The PK samples were not collected at the end of infusion and were therefore outside the protocol-defined time window; consequently, Cmax could not be estimated and N = 0 in IV category. No participants received Azacitidine by SC route, thus N=0 in SC category.
Time frame: Part 1:Dose escalation (dose levels 1 and 2):Pre-dose, 0.5, 1.5, 2.5, 4.5 and 9.5 hours post-dose on Cycle 1 Day 1
Sub-study 1: All 3 Parts: Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity of Azacitidine
Blood samples were collected at specified timepoints to determine AUC of azacitidine during dose escalation part. Participants missed few scheduled site visits for sample collection and only participants with data collected at specified timepoints are reported. PK samples were not collected at the end of infusion; therefore, Cmax could not be estimated. In addition, PK samples collected outside the predefined time window resulted in insufficient data to calculate AUC, thus N=0 in IV category. No participants received Azacitidine by SC route, thus N=0 in SC category.
Time frame: Part 1:Dose escalation (dose levels 1 and 2):Pre-dose, 0.5, 1.5, 2.5, 4.5 and 9.5 hours post-dose on Cycle 1 Day 1
Sub-study 1: All 3 Parts: Number of Participants With Anti-Drug Antibodies (ADAs) Against SAR443579
Plasma samples were collected to assess the antibodies to SAR443579 during dose escalation part. Treatment-emergent ADA was defined as a participant with at least 1 treatment-induced or treatment-boosted ADA-positive sample at any time during the treatment or follow-up observation period. Non-treatment emergent ADA was defined as participant without any treatment-induced, treatment-boosted ADA-positive or ADA-inconclusive sample during the treatment or follow-up observation period.
Time frame: Part 1:Dose escalation (dose levels 1 and 2): first dose of study drug administration (Day 1) up to early termination of the study, maximum treatment duration was 31.3 weeks
Sub-study 1: Part 3: Dose Expansion: Composite Complete Remission (CRc) Rate
The CRc rate was defined as the percentage of participants who had a response of CR, CRh or CRi as best overall response as assessed by the Investigator according to 2022 ELN recommendations for diagnosis and management of AML.
Time frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
Sub-study 1: Part 3: Dose Expansion: Overall Response Rate
The ORR was defined as the percentage of participants who had a response of CR or CRi or CRh or partial remission (PR) or MLFS (morphological leukemia-free state) as best overall response as assessed by the Investigator according to the 2022 ELN criteria.
Time frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
Sub-study 1: Part 3: Dose Expansion: Duration of Complete Remission
Duration of CR was defined as the time interval from the first documented evidence of CR until disease relapse as determined by the Investigator as per 2022 ELN recommendations or death due to any cause, whichever occurred first.
Time frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
Sub-study 1: Part 3: Dose Expansion: Duration of Composite Complete Remission
Duration of CRc was defined as the time interval from first documented evidence of CRc (CR, CRh or CRi) until disease relapse as determined by the Investigator as per 2022 ELN recommendations or death due to any cause, whichever occurred first.
Time frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
Sub-study 1: Part 3: Dose Expansion: Duration of Overall Response Rate
Duration of overall response rate was defined as the time from the first documented evidence of CR or CRi or CRh or PR or MLFS until disease relapse as determined by the Investigator as per 2022 ELN recommendations or death due to any cause, whichever occurred first.
Time frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
Sub-study 1: Part 3: Dose Expansion: Alternative Complete Remission Rate
Alternative CR rate was defined as percentage of participants with alternative CR or CRh as best overall response as assessed by the Investigator.
Time frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
Sub-study 1: Part 3: Dose Expansion: Duration of Alternative Complete Remission
Duration of alternative CR was defined as the time from the first documented evidence of alternative CR or CRh until disease relapse as determined by the Investigator as per 2022 ELN recommendations or death due to any cause, whichever occurred first.
Time frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
Sub-study 1: Part 3: Dose Expansion: Event-Free Survival (EFS)
The EFS was defined as the time interval from the first day of treatment assignment until treatment failure, relapse from remission, or death from any cause, whichever occurred first.
Time frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
Sub-study 1: Part 3: Dose Expansion: Overall Survival (OS)
The OS was defined as time interval from the day of treatment assignment to death from any cause.
Time frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
Sub-study 1: Part 3: Dose Expansion: Percentage of Participants With Hematopoietic Stem Cell Transplantation (HSCT)
The HSCT rate was defined as the percentage of such participants who underwent HSCT through study treatment but before subsequent therapy, among the safety/exposed population.
Time frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
Sub-study 1: Part 3: Dose Expansion: Time to Treatment Failure (TTF)
The TTF was defined as the time from first day of treatment assignment to the first discontinuation for any reason excluding remission, that is, relapsed disease, refractory disease, unacceptable AE, participant preference or death, whichever occurred first.
Time frame: Tumor assessments were planned to be performed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until relapsed disease, refractory disease, unacceptable AE, participant preference or death due to any cause, whichever occurred first
Sub-study 1: All 3 Parts: Transfusion Independence (TI) Rate
The TI rate was defined differently for participants who were transfusion dependent (TD) at baseline and participants who were transfusion independent (TI) at baseline. For subgroup of participants with TD at baseline, the TI rate was defined as the percentage of participants who converted from baseline TD to TI during on treatment period; For subgroup of participants with TI at baseline, the TI rate was defined as the percentage of participants who remained TI during 56-day post baseline period during treatment.
Time frame: Part 1:Dose escalation (dose levels 1 and 2): From Baseline (Day 1, before 1st dose of study treatment administration) to 56 days post-baseline during treatment period (Maximum exposure duration: 31.3 weeks)
The study was conducted at 7 sites in 2 countries. A total of 10 participants were screened from 13-Aug-2024 to 03-Apr-2025, of which 3 were screen failures mainly due to not meeting eligibility criteria. A total of 7 participants with CD123-expressing newly diagnosed acute myeloid leukemia (NDAML) who were ineligible for intensive chemotherapy were enrolled. Two sub-studies 1 and 2 were planned with 3 parts in each (Part 1: Dose escalation, Part 2: Dose optimization, Part 3: Dose expansion).
| Milestone | Sub-study 1: Part 1: Dose Escalation: SAR443579 0.6 mg/kg + Venetoclax + Azacitidine | Sub-study 1: Part 1: Dose Escalation: SAR443579 1 mg/kg + Venetoclax + Azacitidine |
|---|---|---|
| Started | 4 | 3 |
| Completed | 0 | 0 |
| Not completed | 4 | 3 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Progressive disease | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Other-as reported by the investigator | 1 | 2 |
DLT=any of the following events during Cycle 1 (first 28 days) using NCI CTCAE v5.0 or ASTCT criteria, whether related or not to study treatment in absence of clear evidence to the contrary, and if not related to disease progression. Hematologic DLTs :toxicities, bone marrow hypocellularity, decreased neutrophils, febrile neutropenia, decreased platelets, anemia (all Grade 4) and Grade 3 thrombocytopenia. Non-hematologic DLTs: organ toxicities or infusion reaction (both Grade 4), Grade 3 infusion reaction lasting \>24 hours, Hy's law cases, Grade 3-4 infection, Grade 3 electrolyte abnormalities or transaminitis elevation, Grade \>=3 toxicities except alopecia, Grade 3 fatigue, asthenia, fever, anorexia, constipation, nausea, vomiting, diarrhea, infection, bleeding, Grade 3 cytokine release syndrome or laboratory abnormalities, Grade 3 or 4 tumor lysis syndrome. Any treatment related toxicity causing \>2-week delay in recovery to baseline/Grade \<=1 or requiring dose reduction/withdrawal.
| Participants | Sub-study 1: Part 1: Dose Escalation: SAR443579 0.6 mg/kg + Venetoclax + Azacitidine | Sub-study 1: Part 1: Dose Escalation: SAR443579 1 mg/kg + Venetoclax + Azacitidine |
|---|---|---|
| Sub-study 1: Part 1: Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLTs) | 1 | 1 |
An AE was any untoward medical occurrence in participant or clinical study participant temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE was any AE, that at any dose: resulted in death, was life-threatening, required inpatient hospitalization/prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was a medically important event. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required. The TEAEs were defined as AEs that developed, worsened or became serious after the first administration of study treatment up to 30 days after the last administration of study treatment.
No measurements were reported for this outcome.
Blood samples were planned to be collected to determine the PCSA in hematology.
No measurements were reported for this outcome.
Blood samples were planned to be collected to determine the PCSA in clinical chemistry.
No measurements were reported for this outcome.
The CR rate was defined as percentage of participants who had a CR determined by the Investigator according to 2022European Leukemia Net (ELN) recommendations for diagnosis and management of AML.
No measurements were reported for this outcome.
The CR rate was defined as percentage of participants who had a CR determined by the Investigator according to 2022 European Leukemia Net (ELN) recommendations for diagnosis and management of AML.
No measurements were reported for this outcome.
An AE was any untoward medical occurrence in participant or clinical study participant temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE was any AE, that at any dose: resulted in death, was life-threatening, required inpatient hospitalization/prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was a medically important event. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required. TEAEs: AEs that developed, worsened/became serious after first administration of study treatment up to 30 days after last administration of study treatment.
| Participants | Sub-study 1: Part 1: Dose Escalation: SAR443579 0.6 mg/kg + Venetoclax + Azacitidine | Sub-study 1: Part 1: Dose Escalation: SAR443579 1 mg/kg + Venetoclax + Azacitidine |
|---|---|---|
| TEAEs | 4 | 3 |
| TESAEs | 3 | 2 |
| TEAESIs | 1 | 2 |
The minimal residual disease rate was defined as the percentage of participants with minimal residual disease as defined by 2022 ELN in participants achieving a CR, CR with partial hematologic recovery (CRh) or CR with incomplete hematologic recovery (CRi).
No measurements were reported for this outcome.
Blood samples were collected just before treatment administration during repeated dosing to determine the Ctrough of SAR443579 during dose escalation part. Participants missed few scheduled site visits for sample collection and only participants with data collected at specified timepoints are reported.
| nanograms per milliliter (ng/mL) | Sub-study 1: Part 1: Dose Escalation: SAR443579 0.6 mg/kg + Venetoclax + Azacitidine | Sub-study 1: Part 1: Dose Escalation: SAR443579 1 mg/kg + Venetoclax + Azacitidine |
|---|---|---|
| Cycle 1 Day 1 | 75.000 ± 0.000 | 118.750 ± 58.336 |
| Cycle 1 Day 8 | 89.667 ± 25.403 | 75.000 |
| Cycle 1 Day 15 | 427.400 ± 608.470 | 1654.500 ± 1195.718 |
| Cycle 1 Day 22 | 861.650 ± 1100.753 | 3810.000 ± 3577.960 |
| Cycle 2 Day 8 | 76.150 ± 1.626 | 2470.500 ± 2431.740 |
| Cycle 2 Day 15 | 121.500 ± 65.761 | 4020.000 ± 4214.356 |
| Cycle 2 Day 22 | 530.000 ± 596.798 | 1800.000 |
| Cycle 2 Day 28 | 135.000 | — |
Blood samples were collected at specified timepoints to determine Cmax of venetoclax during dose escalation part. Participants missed few scheduled site visits for sample collection and only participants with data collected at specified timepoints are reported.
| ng/mL | Sub-study 1: Part 1: Dose Escalation: SAR443579 0.6 mg/kg + Venetoclax + Azacitidine | Sub-study 1: Part 1: Dose Escalation: SAR443579 1 mg/kg + Venetoclax + Azacitidine |
|---|---|---|
| Cycle 1 Day 1 | 365 ± 211 | 241 ± 287 |
| Cycle 1 Day 8 | 1290 ± 612 | 2360 ± 382 |
Blood samples were collected at specified timepoints to determine AUC of venetoclax during dose escalation part. Participants missed few scheduled site visits for sample collection and only participants with data collected at specified timepoints are reported.
| hour*ng/mL | Sub-study 1: Part 1: Dose Escalation: SAR443579 0.6 mg/kg + Venetoclax + Azacitidine | Sub-study 1: Part 1: Dose Escalation: SAR443579 1 mg/kg + Venetoclax + Azacitidine |
|---|---|---|
| Sub-study 1: All 3 Parts: Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC) of Venetoclax | 4870 ± 1970 | — |
Blood samples were collected at specified timepoints to determine Cmax of azacitidine during dose escalation part. Participants missed few scheduled site visits for sample collection and only participants with data collected at specified timepoints are reported. The PK samples were not collected at the end of infusion and were therefore outside the protocol-defined time window; consequently, Cmax could not be estimated and N = 0 in IV category. No participants received Azacitidine by SC route, thus N=0 in SC category.
| ng/mL | Sub-study 1: Part 1: Dose Escalation: SAR443579 0.6 mg/kg + Venetoclax + Azacitidine | Sub-study 1: Part 1: Dose Escalation: SAR443579 1 mg/kg + Venetoclax + Azacitidine |
|---|---|---|
| IV | — | 1530 |
| SC | 595 ± 66.5 | — |
Blood samples were collected at specified timepoints to determine AUC of azacitidine during dose escalation part. Participants missed few scheduled site visits for sample collection and only participants with data collected at specified timepoints are reported. PK samples were not collected at the end of infusion; therefore, Cmax could not be estimated. In addition, PK samples collected outside the predefined time window resulted in insufficient data to calculate AUC, thus N=0 in IV category. No participants received Azacitidine by SC route, thus N=0 in SC category.
| hour*ng/mL | Sub-study 1: Part 1: Dose Escalation: SAR443579 0.6 mg/kg + Venetoclax + Azacitidine | Sub-study 1: Part 1: Dose Escalation: SAR443579 1 mg/kg + Venetoclax + Azacitidine |
|---|---|---|
| IV | — | 588 |
| SC | 1040 ± 518 | — |
Plasma samples were collected to assess the antibodies to SAR443579 during dose escalation part. Treatment-emergent ADA was defined as a participant with at least 1 treatment-induced or treatment-boosted ADA-positive sample at any time during the treatment or follow-up observation period. Non-treatment emergent ADA was defined as participant without any treatment-induced, treatment-boosted ADA-positive or ADA-inconclusive sample during the treatment or follow-up observation period.
| Participants | Sub-study 1: Part 1: Dose Escalation: SAR443579 0.6 mg/kg + Venetoclax + Azacitidine | Sub-study 1: Part 1: Dose Escalation: SAR443579 1 mg/kg + Venetoclax + Azacitidine |
|---|---|---|
| Sub-study 1: All 3 Parts: Number of Participants With Anti-Drug Antibodies (ADAs) Against SAR443579 | 0 | 0 |
The CRc rate was defined as the percentage of participants who had a response of CR, CRh or CRi as best overall response as assessed by the Investigator according to 2022 ELN recommendations for diagnosis and management of AML.
No measurements were reported for this outcome.
The ORR was defined as the percentage of participants who had a response of CR or CRi or CRh or partial remission (PR) or MLFS (morphological leukemia-free state) as best overall response as assessed by the Investigator according to the 2022 ELN criteria.
No measurements were reported for this outcome.
Duration of CR was defined as the time interval from the first documented evidence of CR until disease relapse as determined by the Investigator as per 2022 ELN recommendations or death due to any cause, whichever occurred first.
No measurements were reported for this outcome.
Duration of CRc was defined as the time interval from first documented evidence of CRc (CR, CRh or CRi) until disease relapse as determined by the Investigator as per 2022 ELN recommendations or death due to any cause, whichever occurred first.
No measurements were reported for this outcome.
Duration of overall response rate was defined as the time from the first documented evidence of CR or CRi or CRh or PR or MLFS until disease relapse as determined by the Investigator as per 2022 ELN recommendations or death due to any cause, whichever occurred first.
No measurements were reported for this outcome.
Alternative CR rate was defined as percentage of participants with alternative CR or CRh as best overall response as assessed by the Investigator.
No measurements were reported for this outcome.
Duration of alternative CR was defined as the time from the first documented evidence of alternative CR or CRh until disease relapse as determined by the Investigator as per 2022 ELN recommendations or death due to any cause, whichever occurred first.
No measurements were reported for this outcome.
The EFS was defined as the time interval from the first day of treatment assignment until treatment failure, relapse from remission, or death from any cause, whichever occurred first.
No measurements were reported for this outcome.
The OS was defined as time interval from the day of treatment assignment to death from any cause.
No measurements were reported for this outcome.
The HSCT rate was defined as the percentage of such participants who underwent HSCT through study treatment but before subsequent therapy, among the safety/exposed population.
No measurements were reported for this outcome.
The TTF was defined as the time from first day of treatment assignment to the first discontinuation for any reason excluding remission, that is, relapsed disease, refractory disease, unacceptable AE, participant preference or death, whichever occurred first.
No measurements were reported for this outcome.
The TI rate was defined differently for participants who were transfusion dependent (TD) at baseline and participants who were transfusion independent (TI) at baseline. For subgroup of participants with TD at baseline, the TI rate was defined as the percentage of participants who converted from baseline TD to TI during on treatment period; For subgroup of participants with TI at baseline, the TI rate was defined as the percentage of participants who remained TI during 56-day post baseline period during treatment.
| percentage of participants | Sub-study 1: Part 1: Dose Escalation: SAR443579 0.6 mg/kg + Venetoclax + Azacitidine | Sub-study 1: Part 1: Dose Escalation: SAR443579 1 mg/kg + Venetoclax + Azacitidine |
|---|---|---|
| Rate of conversion from TD to TI | 0 (0.0 to 77.6) | 0 (0.0 to 63.2) |
| Rate of participants who were TI at baseline and remained independent during treatment period | 0 (0.0 to 77.6) | — |
Collected over SAEs and other AEs were collected from first dose of study drug administration (Day 1) up to early termination of the study, maximum treatment duration was 31.3 weeks for sub-study 1: Part 1: Dose Escalation: DL 1 and 2. All-cause mortality was collected from the first dose of study drug administration (Day 1) up to the longest duration of survival follow up for each participant; maximum duration being 51 weeks 4 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sub-study 1: Part 1: Dose Escalation: SAR443579 0.6 mg/kg + Venetoclax + Azacitidine | 1/4 (25%) | 3/4 (75%) | 4/4 (100%) |
| Sub-study 1: Part 1: Dose Escalation: SAR443579 1 mg/kg + Venetoclax + Azacitidine | 2/3 (66.7%) | 2/3 (66.7%) | 3/3 (100%) |
| Event | Sub-study 1: Part 1: Dose Escalation: SAR443579 0.6 mg/kg + Venetoclax + Azacitidine | Sub-study 1: Part 1: Dose Escalation: SAR443579 1 mg/kg + Venetoclax + Azacitidine |
|---|---|---|
| Infusion Related ReactionInjury, poisoning and procedural complications | 2/4 | 1/3 |
| SepsisInfections and infestations | 1/4 | 1/3 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 0/4 | 1/3 |
| Tumour Lysis SyndromeMetabolism and nutrition disorders | 0/4 | 1/3 |
| Pleural EffusionRespiratory, thoracic and mediastinal disorders | 0/4 | 1/3 |
| PyrexiaGeneral disorders | 0/4 | 1/3 |
| Event | Sub-study 1: Part 1: Dose Escalation: SAR443579 0.6 mg/kg + Venetoclax + Azacitidine | Sub-study 1: Part 1: Dose Escalation: SAR443579 1 mg/kg + Venetoclax + Azacitidine |
|---|---|---|
| EpistaxisRespiratory, thoracic and mediastinal disorders | 2/4 | 2/3 |
| DiarrhoeaGastrointestinal disorders | 2/4 | 2/3 |
| Oedema PeripheralGeneral disorders | 0/4 | 2/3 |
| Infusion Related ReactionInjury, poisoning and procedural complications | 2/4 | 2/3 |
| Decreased AppetiteMetabolism and nutrition disorders | 2/4 | 1/3 |
| ConstipationGastrointestinal disorders | 2/4 | 1/3 |
| Neutrophil Count DecreasedInvestigations | 2/4 | 1/3 |
| Platelet Count DecreasedInvestigations | 2/4 | 1/3 |
| GingivitisInfections and infestations | 0/4 | 1/3 |
| PneumoniaInfections and infestations | 0/4 | 1/3 |
The exposed population included all screened participants who had taken at least 1 dose of study treatment regardless of the amount of study treatment administered.
| Age, Continuous(years) | Sub-study 1: Part 1: Dose Escalation: SAR443579 0.6 mg/kg + Venetoclax + Azacitidine | Sub-study 1: Part 1: Dose Escalation: SAR443579 1 mg/kg + Venetoclax + Azacitidine | Total |
|---|---|---|---|
| Mean | 78.3 ± 3.9 | 66.7 ± 4.2 | 73.3 ± 7.2 |
| Sex: Female, Male(Participants) | Sub-study 1: Part 1: Dose Escalation: SAR443579 0.6 mg/kg + Venetoclax + Azacitidine | Sub-study 1: Part 1: Dose Escalation: SAR443579 1 mg/kg + Venetoclax + Azacitidine | Total |
|---|---|---|---|
| Female | 1 | 0 | 1 |
| Male | 3 | 3 | 6 |
| Race (NIH/OMB)(Participants) | Sub-study 1: Part 1: Dose Escalation: SAR443579 0.6 mg/kg + Venetoclax + Azacitidine | Sub-study 1: Part 1: Dose Escalation: SAR443579 1 mg/kg + Venetoclax + Azacitidine | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 3 | 2 | 5 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Aug 2024 to primary completion in Aug 2025, 11 months.
Results were first posted in Oct 2026, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.